Cargando…
Discovery of a highly selective VEGFR2 kinase inhibitor CHMFL-VEGFR2-002 as a novel anti-angiogenesis agent
Angiogenesis is an essential process in tumor growth, invasion and metastasis. VEGF receptor 2 (VEGFR2) inhibitors targeting tumor angiogenic pathway have been widely used in the clinical cancer treatment. However, most of currently used VEGFR2 kinase inhibitors are multi-target inhibitors which mig...
Autores principales: | Jiang, Zongru, Wang, Li, Liu, Xuesong, Chen, Cheng, Wang, Beilei, Wang, Wenliang, Hu, Chen, Yu, Kailin, Qi, Ziping, Liu, Qingwang, Wang, Aoli, Liu, Jing, Hong, Guangchen, Wang, Wenchao, Liu, Qingsong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7049616/ https://www.ncbi.nlm.nih.gov/pubmed/32140394 http://dx.doi.org/10.1016/j.apsb.2019.10.004 |
Ejemplares similares
-
Discovery and characterization of a novel irreversible EGFR mutants selective and potent kinase inhibitor CHMFL-EGFR-26 with a distinct binding mode
por: Hu, Chen, et al.
Publicado: (2017) -
Irreversible inhibition of BTK kinase by a novel highly selective inhibitor CHMFL-BTK-11 suppresses inflammatory response in rheumatoid arthritis model
por: Wu, Hong, et al.
Publicado: (2017) -
Discovery and characterization of a novel potent type II native and mutant BCR-ABL inhibitor (CHMFL-074) for Chronic Myeloid Leukemia (CML)
por: Liu, Feiyang, et al.
Publicado: (2016) -
Discovery of a highly selective KIT kinase primary V559D mutant inhibitor for gastrointestinal stromal tumors (GISTs)
por: Yu, Kailin, et al.
Publicado: (2017) -
Discovery of a highly potent and selective Bruton’s tyrosine kinase inhibitor avoiding impairment of ADCC effects for B-cell non-Hodgkin lymphoma
por: Liu, Juan, et al.
Publicado: (2020)